Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.


This Phase I study of 1alpha-hydroxyvitamin D(2), an p.o. administered vitamin D analogue, in patients with advanced hormone-refractory prostate cancer was designed to assess the toxicity, pharmacokinetic and biological markers of drug activity, and lastly tumor response data to recommend a dose for Phase II studies. 1alpha-Hydroxyvitamin D(2) was… (More)


  • Presentations referencing similar topics